Capmatinib-induced interstitial lung disease: A case report
Unstructured abstract: Capmatinib, a highly specific MET inhibitor, was recently approved by the FDA for use in MET exon 14 skipping mutation-positive NSCLC. Although it is usually well tolerated, we describe the first case of a patient who incurred severe pneumonitis linked to this treatment.A 76 y...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621920300247 |